Recent Advances in Onco-Rheumatology

Dear Colleagues,

The rapidly evolving field of onco-rheumatology represents a critical intersection between oncology and rheumatology, addressing the complex challenges arising from the management of patients with concurrent malignancies and autoimmune conditions. With the widespread adoption of immune checkpoint inhibitors (ICIs) and other cancer immunotherapies, we are witnessing an unprecedented rise in immune-related adverse events (irAEs), particularly rheumatic manifestations affecting approximately 5-10% of patients receiving these treatments.

This Special Issue aims to advance our understanding of the multifaceted relationships between cancer and rheumatic diseases, encompassing paraneoplastic rheumatic syndromes, cancer-associated autoimmunity, and the management of patients with pre-existing autoimmune diseases requiring cancer treatment. We seek contributions that explore the pathophysiological mechanisms underlying onco-rheumatologic conditions, diagnostic challenges in distinguishing cancer-related rheumatic symptoms from traditional autoimmune diseases, and evidence-based therapeutic strategies that optimize both cancer outcomes and rheumatic disease control.

We particularly welcome manuscripts addressing the transdisciplinary approach required for optimal patient care, including collaborative management strategies between oncologists and rheumatologists. Contributions may include original research, systematic reviews, case series, and perspectives on emerging therapeutic targets, biomarkers for early detection of rheumatic irAEs, and long-term outcomes in this unique patient population.

Dr. Kosaku Murakami
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• onco-rheumatology
• immune checkpoint inhibitors
• immune-related adverse events
• autoimmune diseases
• cancer-associated autoimmunity